GlassScriptPhysician profile
Christopher Brad Redden
NPI 1689984452
$2,405.00
in general payments reported to CMS, 2019-2025
27 companies · $511 in 2025
The $511 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $449 · 2023: $575 · 2024: $482 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.78 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $218.06 | 2022-2024 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.27 | 2023-2025 | Xifaxan |
| Novo Nordisk INC | $139.15 | 2021-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.74 | 2021-2025 | Jardiance |
| Pfizer INC. | $136.74 | 2023-2025 | |
| Glaxosmithkline, LLC. | $117.88 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $111.65 | 2021 | |
| Lundbeck LLC | $107.12 | 2023-2025 | Rexulti |
| Dexcom, INC. | $93.74 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $82.33 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.59 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $56.80 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $43.95 | 2021-2024 | Airsupra |
| Ultragenyx Pharmaceutical INC. | $42.58 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.39 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $39.62 | 2023 | Quviviq |
| Exact Sciences Corporation | $32.18 | 2025 | The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $29.97 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $29.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.90 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.88 | 2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $19.88 | 2024 | Spravato |
| Gilead Sciences, INC. | $18.58 | 2025 | |
| Eisai INC. | $16.80 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.61 | 2023 | Austedo |
| Paratek Pharmaceuticals, INC. | $15.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Redden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.